BioAffinity Technologies Inc (BIAF) Stock Price

1.08 ▼ -0.01 (-0.92%)
Open: 1.09 Vol: 0 Day's range: 1.07 - 1.09 Feb 26, 11:01 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
BIAF Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.08▲ 1.08▼ 1.08▼ 1.06▲ 1.04▲
MA10 1.07▲ 1.08▲ 1.08▲ 1.08▼ 1.16▼
MA20 1.07▲ 1.06▲ 1.02▲ 1.04▲ 1.55▼
MA50 1.05▲ 1.10▼ 1.08▼ 1.19▼ 1.10▼
MA100 1.11▼ 1.04▲ 1.06▲ 1.66▼ 1.35▼
MA200 1.09▼ 1.15▼ 1.17▼ 1.16▼ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD 0.000▼ 0.004▲ 0.009▲ 0.019▲ -0.096▼
RSI 53.708▲ 52.687▲ 52.704▲ 48.114▼ 45.476▼
STOCH 68.452     61.859     71.474     40.041     32.436    
WILL %R -25.000▲ -46.154     -14.354▲ -46.477     -64.719    
CCI 46.154     40.798     54.328     36.409     -100.698▼
Latest Filters Detected On BIAF
MA $BIAF Price Crossed Below MA(7) Set Alert
CDL $BIAF Doji Candlestick Pattern Detected Set Alert
BioAffinity Technologies Inc News
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung ...
Wednesday, February 25, 2026 08:46 AM
Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® LungSAN ANTONIO--(BUSINESS WIRE)--$BIAF #BAMC--bioAffinity Technologies, Inc. (Nasdaq: BIAF; ...
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
Thursday, February 19, 2026 11:01 AM
CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedureDespite a suspicious nodule during a ...
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
Tuesday, February 17, 2026 05:39 AM
SAN ANTONIO, Texas, February 17, 2026--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.
BIAF historical stock data
date open high low close volume
26/02/26 1.09 1.09 1.07 1.08 15,121
25/02/26 1.09 1.0999 1.03 1.09 102,243
24/02/26 0.93 1.11 0.9009 1.11 190,822
23/02/26 1.06 1.0683 0.90 0.9305 214,111
20/02/26 1.17 1.17 1.05 1.08 224,623
19/02/26 1.22 1.39 1.17 1.18 2,114,170
18/02/26 1.09 1.18 1.03 1.15 178,064
17/02/26 1.04 1.12 0.97 1.07 188,641
13/02/26 1.09 1.1699 1.03 1.04 194,148
12/02/26 0.985 1.1699 0.98 1.10 182,285
Quote Details
52wk Low:0.134
52wk High:7.29
Vol:0
Avg Vol(3m):2.9M
1Y Chng:+194.28%
1M Chng:-14.29%
Add to Watch List
More Information
Index US Composite
Market Cap. 4.99M